ID   KYSE-220
AC   CVCL_1359
AS   CVCL_9819
SY   KYSE 220; KYSE220; KY-220
DR   CLO; CLO_0009933
DR   ArrayExpress; E-MTAB-3610
DR   BioGRID_ORCS_Cell_line; 920
DR   BioSample; SAMN03472505
DR   cancercelllines; CVCL_1359
DR   Cell_Model_Passport; SIDM00551
DR   CGH-DB; 283-1
DR   CGH-DB; 9232-4
DR   Cosmic; 918530
DR   Cosmic; 1043241
DR   Cosmic; 1581076
DR   Cosmic; 1995476
DR   Cosmic; 2650633
DR   Cosmic; 2698439
DR   Cosmic-CLP; 1240167
DR   DepMap; ACH-002263
DR   EGA; EGAS00001000978
DR   GDSC; 1240167
DR   GEO; GSM827502
DR   GEO; GSM1670019
DR   IARC_TP53; 7683
DR   JCRB; JCRB1086
DR   JCRB; NIHS0365
DR   LINCS_LDP; LCL-1559
DR   PharmacoDB; KYSE220_804_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1359
DR   Wikidata; Q54900812
RX   PubMed=1728357;
RX   PubMed=7913084;
RX   PubMed=8575860;
RX   PubMed=9033652;
RX   PubMed=11092977;
RX   PubMed=15172977;
RX   PubMed=16045545;
RX   PubMed=20215515;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Japanese.
CC   Doubling time: 20.5 hours (PubMed=1728357).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.His83Tyr (c.247C>T) (p.Ala97Val, c.290C>T); ClinVar=VCV000376307; Zygosity=Unspecified (PubMed=9033652).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Unspecified (PubMed=8575860).
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0.96%; Native American=0%; East Asian, North=75.9%; East Asian, South=20.19%; South Asian=0%; European, North=1.79%; European, South=1.15% (PubMed=30894373).
CC   Discontinued: JCRB; NIHS0365; true.
CC   Derived from site: In situ; Esophagus; UBERON=UBERON_0001043.
ST   Source(s): Cosmic-CLP; JCRB
ST   Amelogenin: X
ST   CSF1PO: 10
ST   D13S317: 8,9
ST   D16S539: 11
ST   D5S818: 11
ST   D7S820: 12
ST   TH01: 9
ST   TPOX: 11
ST   vWA: 18
DI   NCIt; C4024; Esophageal squamous cell carcinoma
DI   ORDO; Orphanet_99977; Squamous cell carcinoma of the esophagus
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   78Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 36
//
RX   PubMed=1728357; DOI=10.1002/1097-0142(19920115)69:2<277::AID-CNCR2820690202>3.0.CO;2-C;
RA   Shimada Y., Imamura M., Wagata T., Yamaguchi N., Tobe T.;
RT   "Characterization of 21 newly established esophageal cancer cell
RT   lines.";
RL   Cancer 69:277-284(1992).
//
RX   PubMed=7913084; DOI=10.1002/ijc.2910580224;
RA   Kanda Y., Nishiyama Y., Shimada Y., Imamura M., Nomura H., Hiai H.,
RA   Fukumoto M.;
RT   "Analysis of gene amplification and overexpression in human
RT   esophageal-carcinoma cell lines.";
RL   Int. J. Cancer 58:291-297(1994).
//
RX   PubMed=8575860; DOI=10.1002/(SICI)1097-0215(19960126)65:3<372::AID-IJC16>3.0.CO;2-C;
RA   Tanaka H., Shibagaki I., Shimada Y., Wagata T., Imamura M.,
RA   Ishizaki K.;
RT   "Characterization of p53 gene mutations in esophageal squamous cell
RT   carcinoma cell lines: increased frequency and different spectrum of
RT   mutations from primary tumors.";
RL   Int. J. Cancer 65:372-376(1996).
//
RX   PubMed=9033652; DOI=10.1002/(SICI)1097-0215(19970207)70:4<437::AID-IJC11>3.0.CO;2-C;
RA   Tanaka H., Shimada Y., Imamura M., Shibagaki I., Ishizaki K.;
RT   "Multiple types of aberrations in the p16 (INK4a) and the p15(INK4b)
RT   genes in 30 esophageal squamous-cell-carcinoma cell lines.";
RL   Int. J. Cancer 70:437-442(1997).
//
RX   PubMed=11092977; DOI=10.1111/j.1349-7006.2000.tb00895.x;
RA   Pimkhaokham A., Shimada Y., Fukuda Y., Kurihara N., Imoto I.,
RA   Yang Z.-Q., Imamura M., Nakamura Y., Amagasa T., Inazawa J.;
RT   "Nonrandom chromosomal imbalances in esophageal squamous cell
RT   carcinoma cell lines: possible involvement of the ATF3 and CENPF genes
RT   in the 1q32 amplicon.";
RL   Jpn. J. Cancer Res. 91:1126-1133(2000).
//
RX   PubMed=15172977; DOI=10.1158/0008-5472.CAN-04-0172;
RA   Sonoda I., Imoto I., Inoue J., Shibata T., Shimada Y., Chin K.,
RA   Imamura M., Amagasa T., Gray J.W., Hirohashi S., Inazawa J.;
RT   "Frequent silencing of low density lipoprotein receptor-related
RT   protein 1B (LRP1B) expression by genetic and epigenetic mechanisms in
RT   esophageal squamous cell carcinoma.";
RL   Cancer Res. 64:3741-3747(2004).
//
RX   PubMed=16045545; DOI=10.1111/j.0959-9673.2005.00431.x;
RA   Ban S., Michikawa Y., Ishikawa K.-i., Sagara M., Watanabe K.,
RA   Shimada Y., Inazawa J., Imai T.;
RT   "Radiation sensitivities of 31 human oesophageal squamous cell
RT   carcinoma cell lines.";
RL   Int. J. Exp. Pathol. 86:231-240(2005).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//